Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains and it becomes the most common cause of dementia in the elderly. There is an urgent need for the early diagnosis and treatment of AD to ease caregiver burden and medical costs, as well as improve patients' living activities associated with the dramatic increasing number of affected individuals. Molecular imaging with target-specific probes is contributing to identify the underlying biology in AD, which benefits to the early diagnosis of AD and the evaluation of anti-AD therapy. Molecular imaging probes, such as C-11-PIB, C-11-MP4A, F-18-AV-45, and F-18-FDG, can selectively bind to special bimolecular of AD or accurately accumulate at the location of damage areas, thus become an edge tool for a better management of the diseases in the clinical practice and new drug development. In the past decades, a large variety of probes is being developed and tested to be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Since imaging probes may also help to guide physicians to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug, this paper is to present a perspective of the available imaging probes for AD, classified on different modalities. Meanwhile, recent advances of those probes that have been selected for clinical trials and are at the different stages of the US Food and Drugs Administration (FDA) approval are outlined. Additionally, future directions and specific application of imaging strategies designed for both diagnosis and treatment for AD are discussed.

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection

Recent Research Progress in Fluorescent Probes for Detection of Amyloid- In Vivo

Near-Infrared Fluorescent Probes As Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer’s Disease

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Development of Near-Infrared Fluorescent Probes for Use in Alzheimer’s Disease Diagnosis

Application of Biomarker-Derived Fluorescent Probes for the Detection of Alzheimer's Disease

Targeting Β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes.

Research Progress Of Multi-Functional Fluorescent Probes For Alzheimer'S Disease Monitoring

Development of Near-Infrared Fluorescent Probes for Use in Alzheimers Disease Diagnosis

Light-controlled Fluorescent Probes for Precisely Monitoring Brain Amyloid-Β Aggregates in Alzheimer's Disease

Fluorescent Imaging of Amyloid-β Deposits in Brain: An Overview of Probe Development and a Highlight of the Applications for in vivo Imaging.

Near-infrared Fluorescent Probes for Imaging of Amyloid Plaques in Alzheimer׳s Disease.

Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer’s disease

Shedding Light on Alzheimer's Disease: Recent Advances in Highly Selective Fluorescent Probes

Highly Sensitive Near-Infrared Fluorophores for in Vivo Detection of Amyloid-β Plaques in Alzheimer’s Disease

Smart Near-Infrared Fluorescence Probes with Donor–Acceptor Structure for in Vivo Detection of Β-Amyloid Deposits

D-A-D Fluorogenic Probe for the Rapid Imaging of Amyloid Β Plaques in Vivo

Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease

Dual-functional AIE fluorescent probes for imaging -amyloid plaques and lipid droplets

Molecular Imaging of Alzheimer Disease